Traduction de «procédé à effet de lavis » (Français → Anglais) :

A number of technical elements relating to the reporting of greenhouse gas emissions from sources and removals by sinks, such as GWPs, the scope of greenhouse gases reported and methodological guidance from the IPCC to be used to prepare national greenhouse gas inventories, are currently being discussed under the UNFCCC process.

Therefore, it is appropriate to draw on best practices resulting from the application of harmonised standards adopted by the European Committee for Standardisation on the basis of a remit issued by the Commission in accordance with Directive 98/34/EC of the European Parliament and of the Council of 22 June 1998 laying down a procedure for the provision of information in the field of technical standards and regulations and of rules on Information Society services , such as the harmonised standard concerning general requirements for accreditation bodies accrediting conformity assessment bodies, and the harmonised standard concerning requir ...[+++]ements for greenhouse gas validation and verification bodies for use in accreditation or other forms of recognition, the references of which have been published in the Official Journal of the European Union, as well as Document EA-6/03 and other technical documents developed by the European co-operation for Accreditation or by other bodies.

This Decision lays down the minimum contribution of Member States to meeting the greenhouse gas emission reduction commitment of the Community for the period from 2013 to 2020 for greenhouse gas emissions covered by this Decision, and rules on making these contributions and for the evaluation thereof.

The Directive also includes rules for payment systems which are not based on netting but on gross settlement systems (where each payment order is settled individually on a real time basis as it arises during the day): The proposed Directive would also exempt payment systems from national rules giving retroactive effect to the insolvency of a participant in a payment system, such as the zero-hour rule. Such retroactive effect allows the liquidator of an insolvent institution to challenge payment orders which have already been introduce ...[+++]d into the payment system, thus leading to the unwinding of the settlement operation. This unwinding is highly disruptive and can lead to systemic risk. The same is true for revocation of payment orders. Revocation of a large payment order in a payment system during the settlement process, could lead to systemic risk. The Directive would therefore bar revocation of payment orders after the moment contractually fixed by the payment system participants. The insolvency of a participant in a payment system, insofar as it concerned its dealings with the payment system, would be governed by the insolvency law of the country where the payment system was located, according to the proposed Directive. This would avoid conflicts of law and the ensuing legal uncertainty and thus facilitate cross-border participation in payment systems. Collateral security is pledged by the participants in a payment system in order to secure its exposures against the other participants. When collateral security is provided in a cross-border arrangement, its realisation in case of default of the pledging participant can be hindered by conflicts of law which may either weaken the collateral security or even render it unenforceable. In order to ensure collateral security can be realised immediately and in priority over all other creditors (so as not to jeopardise the liquidity of the other participants in the system, i.e. to avoid systemic risk) in the case of a defaul ...

When I said earlier that crown corporations are required to inform themselves, this would be part of the process where the Department of Foreign Affairs leads in and chairs this interdepartmental and interagency group.

With reference to the side effects experienced by those taking the anti-malarial drug mefloquine (Lariam): (a) provide a detailed update on the clinical study of mefloquine (Lariam) announced by the Department of National Defence in 1997, including trial design, subject inclusion/exclusion criteria, numbers of study subjects recruited to date and participating centres; (b) have reviews been undertaken of the side effects experienced by the Australian, British and Dutch forces, if so what were the results and recommendations, and what steps have been undertaken to implement these recommendations; (c) with regard to the mefloquine (Laria ...[+++]m) used for the prophylaxis of Canadian troops deployed to Somalia, what was the nature of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (d) with regard to the mefloquine (Lariam) used for the prophylaxis of Canadian troops deployed to Somalia, what was the outcome of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (e) what is the date of the insert in the mefloquine (Lariam) package used in Canada today; (f) what is the date of the product monograph for mefloquine (Lariam) used in Canada today; (g) have reviews been undertaken of the insert in the mefloquine (Lariam) package and the prescribing information used in Australia, if so what were the results and recommendations of the reviews, and what steps have been taken to implement the recommendations; (h) have reviews been undertaken ...